Inhibikase Therapeutics Inc
NASDAQ:IKT

  • LAST PRICE
    2.3100
  • TODAY'S CHANGE (%)
    0.3000 (14.9254%)
  • Bid / Lots
    2.2500/ 2
  • Ask / Lots
    2.2800/ 2
  • Open / Previous Close
    2.0200 / 2.0100
  • Day Range
    1.9600
    2.3871
  • 52 Week Range
    0.8500
    3.8200
  • Volume
    199,363

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 14, 2024

      Show headlines and story abstract

    • 8:37AM ET on Thursday Nov 14, 2024 by Dow Jones
      Companies Mentioned: IKT

    • 8:37AM ET on Thursday Nov 14, 2024 by Dow Jones
      Companies Mentioned: IKT
      Lease obligation, current 145,210 150,095 Accrued expenses and other current liabilities 2,161,374 2,259,955 Insurance premium financing payable 71,662 381,784 ----------- ----------- Total current liabilities 4,907,466 3,438,601 Lease obligation, net of current portion -- 90,124 ----------- Total liabilities 4,907,466 3,528,725 ----------- ----------- Commitments and contingencies (see Note 13) Stockholders' equity: Preferred stock, $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding at September 30, 2024 and December 31, 2023 -- -- Common stock, $0.001 par value; 100,000,000 shares authorized; 7,464,070 and 6,186,280 shares issued and outstanding at September 30, 2024 and December 31, 2023 7,464 6,186 Additional paid-in capital 81,748,225 77,871,584 Accumulated other comprehensive (loss) income 1,754 877 Accumulated deficit (82,288,034) (66,900,725) ----------- ----------- Total stockholders' equity (530,591) 10,977,922 ----------- ----------- Total liabilities and stockholders' (deficit) equity $ 4,376,875 $ 14,506,647 Inhibikase Therapeutics, Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Three Months Ended Nine Months Ended September September 30, 30, -------------------------- ------------------------------ 2024 2023 2024 2023 Revenue: Grant revenue $ -- $ 79,569 $ -- $ 260,500 ---------- ---------- ----------- ----------- Total revenue -- 79,569 -- 260,500 ---------- ---------- ----------- ----------- Costs and expenses: Research and development 4,189,873 3,225,551 10,016,982 10,615,368 Selling, general and administrative 1,637,603 1,622,894 5,643,386 5,331,358 ---------- ---------- ----------- ----------- Total costs and expenses 5,827,476 4,848,445 15,660,368 15,946,726 ---------- ---------- ----------- ----------- Loss from operations (5,827,476) (4,768,876) (15,660,368) (15,686,226) Interest income (expense) 49,410 173,677 273,059 835,283 ---------- ---------- ----------- ----------- Net loss (5,778,066) (4,595,199) (15,387,309) (14,850,943) Other comprehensive loss, net of tax Unrealized gains (loss) on marketable securities 2,778 1,571 877 (104,861) ---------- ---------- ----------- ----------- Comprehensive Loss $(5,775,288) $(4,593,628) $(15,386,432) $(14,955,804) ---------- ---------- ----------- ----------- Net loss per share -- basic and diluted $ (0.65) $ (0.75) $ (2.03) $ (2.48) ========== ========== =========== =========== Weighted-average number of common shares -- basic and diluted 8,882,570 6,162,671 7,592,103 5,977,841 ========== ========== =========== ===========

  • Nov 8, 2024

Peers Headlines